Bioage Labs, Inc.(BIOA) - 2024 Q4 - Annual Results

RICHMOND, Calif.--BioAge Labs, Inc. ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging, today provided financial results for the full year ended December 31, 2024 and business updates for the fourth quarter ended December 31, 2024. "The fourth quarter of 2024 was marked by key strategic decisions and solid pipeline progress," said Kristen Fortney, Ph.D., CEO and co-founde ...